On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

Tao JiangJianhua ChenXingxiang XuYing ChengGongyan ChenYueyin PanYong FangQiming WangYunchao HuangWenxiu YaoRui WangXingya LiWei ZhangYanjun ZhangSheng HuRenhua GuoJianhua ShiZhiwu WangPeiguo CaoDonglin WangJian FangHui LuoYi GengChunyan XingDongqing LvYiping ZhangJunyan YuShundong CangYaxi ZhangJiao ZhangZeyu YangWei ShiJianjun ZouCaicun ZhouShengxiang Ren

Published in: Molecular cancer (2022)

ClinicalTrials.gov identifier: NCT03668496.

Keyphrases

phase iii
open label
squamous cell carcinoma
clinical trial
phase ii
double blind
placebo controlled
locally advanced
study protocol
randomized controlled trial
radiation therapy